Dr Martens PLC (LSE:DOCS) reported a 10% drop in group revenue to £787.6 million for the year ended 30 March 2025, amidst a marketing 'reset'. Adjusted profit before tax fell to £34.1 million from £97.2 million, the boot brand said in the results statement.
His concentrated portfolio strategy, focusing on high-quality, long-term holdings, reflects a disciplined, tech-heavy investment approach.
DOCS posts strong Q4 revenue growth and record user engagement as demand for telehealth and AI tools hits new highs.
Dr Martens PLC (LSE:DOCS) shares stumbled to a new all-time low below 50p last month after the US tariff announcement, but have been tiptoeing higher in the run-up to interim results due next Thursday, 5 June. Back in January, the boot-maker flagged "good progress" in its turnaround after revenue ticked up 3% on a constant currency basis during the third quarter, aided by stronger American and Asia Pacific sales, offsetting a decline in Europe due to strong promotional activity from rivals in December.
DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.
Doximity, Inc. (NYSE:DOCS ) Q4 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Perry Gold - Head of IR Jeff Tangney - Co-Founder and CEO Anna Bryson - CFO Nate Gross - Co-Founder and CSO Conference Call Participants Brian Peterson - Raymond James Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Ryan MacDonald - Needham Jared Haase - William Blair Allen Lutz - Bank of America Scott Schoenhaus - KeyBanc Ann Samuel - JPMorgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Steven Veliquette - Mizuho Securities Jeff Garro - Stephens David Roman - Goldman Sachs Jailendra Singh - Truist Craig Hettenbach - Morgan Stanley Operator Good day, everyone, and welcome to the Doximity Q4 2025 Earnings Call. At this time, I will hand the call over to Perry Gold, Head of IR.
Doximity (DOCS) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.25 per share a year ago.
Shares of Doximity plummeted late Thursday after the telehealth software company dished out a disappointing outlook.
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
In the closing of the recent trading day, Doximity (DOCS) stood at $56.65, denoting a +0.64% change from the preceding trading day.
Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment?
Doximity (DOCS) closed at $60.55 in the latest trading session, marking a -1.51% move from the prior day.